NCT06017557Recruiting
Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer
Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer, Using a Machine Learning Algorithm and Patterns of Disease Distribution at Laparoscopy (PREDAtOOR)
Source: ClinicalTrials.gov · Last updated 19 Dec 2025
Brief summary (registry, in English)
PREDAtOOR is a pilot study and this study aims at improving the selection of the best treatment strategy for patients with advanced ovarian cancer by using Camera Vision (CV) to predict outcomes of cyto reduction at the time of Diagnostic laparoscopy.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 151 (estimated)
- First submitted
- 10 Aug 2023
- Start date
- 2 Jan 2023
- Primary completion date
- 15 Dec 2025
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Diseases
- Ovarian cancer
- NCT number
- NCT06017557
What you commit to
- Study type: Interventional
- Planned participants: 151
- From 2 Jan 2023 to the primary completion date, 15 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients unfit for surgery
- Lack of information about patients' surgical outcomes and clinicopathological characteristics
Other illness
- Patients with pre-operative Stage I-II disease confined to the pelvis
Other
- LGSOC, Clear cell and mucinous, non-epithelial histologic subtypes (if available)
Who the study is looking for
- Patients treated at Fondazione Policlinico Gemelli Hospital, Rome Italy, Trillium -Credit Valley Hospital, Mississauga, Ontario and Princess Margaret Cancer Centre, Toronto, Canada
- Patients fit for cytoreductive surgery
- Patients with a primary diagnosis of suspect Stage III-IV ovarian cancer
- Patients selected for interval cytoreductive surgery after NACT
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Ginecologia Oncologica Coordinator of this site? Confirm its status | Roma | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.